Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

129.34
-3.5500-2.67%
Post-market: 129.930.5900+0.46%17:00 EDT
Volume:1.54M
Turnover:199.70M
Market Cap:18.96B
PE:12.37
High:132.67
Open:132.42
Low:128.90
Close:132.89
Loading ...

Biogen Shares up 5.6% After Co Lifts FY Profit Forecast

THOMSON REUTERS
·
31 Jul

Biogen Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
31 Jul

Biogen Exec Says Co Expects "Accelerating Competitive Pressures" on Multiple Sclerosis Business Outside US in H2 2025 -Conf Call

THOMSON REUTERS
·
31 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Carvana, Cigna

Reuters
·
31 Jul

Stock Track | Biogen Surges 6.60% Pre-market on Strong Q2 Results and Raised 2025 Outlook

Stock Track
·
31 Jul

Earnings Flash (BIIB) Biogen Posts Q2 Non-GAAP EPS $5.47, vs. FactSet Est of $3.90

MT Newswires Live
·
31 Jul

Biogen Raises Annual Profit Forecast on Strong Demand for Rare Disease Drugs

Reuters
·
31 Jul

BUZZ-Biogen climbs after lifting annual profit estimates

Reuters
·
31 Jul

Biogen reports Q2 adjusted EPS $5.47, consensus $3.87

TIPRANKS
·
31 Jul

BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00

Reuters
·
31 Jul

Biogen Q2 2025 Adj. EPS $5.47 Beats $4.06 Estimate, Sales $2.646B Beat $2.319B Estimate

Benzinga
·
31 Jul

Biogen raises FY25 adjusted EPS view to $15.50-$16.00 from $14.50-$15.50

TIPRANKS
·
31 Jul

BRIEF-Biogen Q2 Adjusted EPS USD 5.47 Vs. IBES Estimate USD 3.86

Reuters
·
31 Jul

Biogen Q2 Revenue USD 2,600 Million VS. Ibes Estimate USD 2,323 Million

THOMSON REUTERS
·
31 Jul

Biogen Q2 EPS USD 4.33

THOMSON REUTERS
·
31 Jul

Biogen raises annual profit estimates on strong demand for rare disease drugs

Reuters
·
31 Jul

Biogen -Q2 Non-Gaap Diluted EPS $5.47

THOMSON REUTERS
·
31 Jul

Biogen -Financial Outlook Is Not Currently Expected to Be Materially Impacted by Potential Tariffs

THOMSON REUTERS
·
31 Jul

Biogen -Increased Expected Full Year 2025 Total Revenue to Be Approximately Flat, at Constant Currency

THOMSON REUTERS
·
31 Jul

Biogen -Expects Increased Competitive Pressures on Ex- U.S. MS Business in Second Half of 2025

THOMSON REUTERS
·
31 Jul